TY - JOUR
T1 - Lipidomic analysis of surfactant and plasma from horses with asthma and age-matched healthy horses
AU - Christmann, Undine
AU - Page, Allen E
AU - Horohov, David W
AU - Adams, Amanda A
AU - Chapman, Seth E
AU - Hancock, Courtney L
AU - Emery, Audrey L
AU - Poovey, Jesse R
AU - Hagg, Casey
AU - Ortega Morales, Saira M
AU - Duncan, Ashley R
AU - Morgan, Joey
AU - Couetil, Laurent L
AU - Morresey, Peter
AU - Wood, Paul L
PY - 2022/7/11
Y1 - 2022/7/11
N2 - OBJECTIVE: To perform lipidomic analysis of surfactant and plasma from asthmatic and healthy horses.ANIMALS: 30 horses with clinical signs of asthma and 30 age-matched control horses.PROCEDURES: Detailed history, physical examination, CBC, and bronchoalveolar lavage fluid (BALF) cytologies were obtained. Asthmatic horses were grouped based on their BALF inflammatory profile: severe equine asthma (SEA), mild equine asthma with neutrophilic airway inflammation (MEA-N), or mild equine asthma with eosinophilic airway inflammation (MEA-E). Each asthma group was assigned its own age-matched control group. Lipidomic analysis was completed on surfactant and plasma. Surfactant protein D (SP-D) concentrations were measured in serum and BALF.RESULTS: SEA surfactant was characterized by a phospholipid deficit and altered composition (increased ceramides, decreased phosphatidylglycerol, and increased cyclic phosphatidic acid [cPA]). In comparison, MEA-N surfactant only had a decrease in select phosphatidylglycerol species and increased cPA levels. The plasma lipidomic profile was significantly different in all asthma groups compared to controls. Specifically, all groups had increased plasma phytoceramide. SEA horses had increased plasma cPA and diacylglycerol whereas MEA-N horses only had increased cPA. MEA-E horses had increases in select ceramides and dihydrocermides. Only SEA horses had significantly increased serum SP-D concentrations.CLINICAL RELEVANCE: The most significant surfactant alterations were present in SEA (altered phospholipid content and composition); only mild changes were observed in MEA-N horses. The plasma lipidomic profile was significantly altered in all groups of asthmatic horses and differed among groups. Data from a larger population of asthmatic horses are needed to assess implications for diagnosis, prognosis, and treatment.
AB - OBJECTIVE: To perform lipidomic analysis of surfactant and plasma from asthmatic and healthy horses.ANIMALS: 30 horses with clinical signs of asthma and 30 age-matched control horses.PROCEDURES: Detailed history, physical examination, CBC, and bronchoalveolar lavage fluid (BALF) cytologies were obtained. Asthmatic horses were grouped based on their BALF inflammatory profile: severe equine asthma (SEA), mild equine asthma with neutrophilic airway inflammation (MEA-N), or mild equine asthma with eosinophilic airway inflammation (MEA-E). Each asthma group was assigned its own age-matched control group. Lipidomic analysis was completed on surfactant and plasma. Surfactant protein D (SP-D) concentrations were measured in serum and BALF.RESULTS: SEA surfactant was characterized by a phospholipid deficit and altered composition (increased ceramides, decreased phosphatidylglycerol, and increased cyclic phosphatidic acid [cPA]). In comparison, MEA-N surfactant only had a decrease in select phosphatidylglycerol species and increased cPA levels. The plasma lipidomic profile was significantly different in all asthma groups compared to controls. Specifically, all groups had increased plasma phytoceramide. SEA horses had increased plasma cPA and diacylglycerol whereas MEA-N horses only had increased cPA. MEA-E horses had increases in select ceramides and dihydrocermides. Only SEA horses had significantly increased serum SP-D concentrations.CLINICAL RELEVANCE: The most significant surfactant alterations were present in SEA (altered phospholipid content and composition); only mild changes were observed in MEA-N horses. The plasma lipidomic profile was significantly altered in all groups of asthmatic horses and differed among groups. Data from a larger population of asthmatic horses are needed to assess implications for diagnosis, prognosis, and treatment.
KW - Animals
KW - Asthma/diagnosis
KW - Bronchoalveolar Lavage Fluid
KW - Ceramides
KW - Horse Diseases/metabolism
KW - Horses
KW - Inflammation/veterinary
KW - Lipidomics
KW - Phosphatidylglycerols
KW - Phospholipids
KW - Pulmonary Surfactant-Associated Protein D
KW - Pulmonary Surfactants/metabolism
KW - Surface-Active Agents
U2 - 10.2460/ajvr.21.11.0179
DO - 10.2460/ajvr.21.11.0179
M3 - Article
C2 - 35895773
SN - 0002-9645
VL - 83
JO - American Journal of Veterinary Research
JF - American Journal of Veterinary Research
IS - 9
ER -